2024年8月5日 · Surfaxin is a lung surface acting agent, or "surfactant." It helps the lungs function normally. Surfaxin is used to treat or prevent respiratory distress syndrome (RDS) in a premature baby whose lungs have not fully developed.

Surfact 108mg Injection is a natural lung surfactant called as dipalmitoyl phosphatidylcholine that lubricates the linings of the air spaces in lungs, thereby enabling normal breathing. It is effective in newborn babies who have difficulty in breathing due to lack of enough surfactant in their lungs.

Pulmonary surfactant is used as a medication to treat and prevent respiratory distress syndrome in newborn babies. [1] Prevention is generally done in babies born at a gestational age of less than 32 weeks. [1] It is given by the endotracheal tube. [1] Onset of effects is rapid. [2] A number of doses may be needed. [2]

Surfactant has revolutionized the treatment of respiratory distress syndrome and some other respiratory conditions that affect the fragile neonatal lung. Despite its widespread use, the optimal method of surfactant administration in preterm infants has yet to be clearly determined.

Surfact 108 Injection is a lung surfactant used for the prevention and treatment of respiratory distress syndrome in newborn babies with a birth weight of 700 grams or greater, undergoing mechanical ventilation. Close monitoring of heart rate and arterial oxygenation is recommended during treatment with this medicine.

Preterm neonates with RDS should be stabilized on CPAP and if indicated selective surfactant replacement therapy should be administered. Sub-group considerations: Clinicians may consider delivery room surfactant in subgroup of neonates <28 weeks’ gestation who are intubated in the delivery room for severe RDS. 2.

Surfactant deficiency is a recognized cause of respiratory distress syndrome in the preterm neonate. Secondary surfactant deficiency also contributes to acute respiratory morbidity in late-preterm and term neonates with meconium aspiration syndrome, pulmonary haemorrhage, and pneumonia/sepsis.

Surfactant therapy has been shown to decrease pneumothorax and improve newborn and infant survival. 1 Timing of surfactant administration, fraction of inspired oxygen (FIO 2) criteria for first dose of surfactant, and method of surfactant administration using a thin catheter or an endotracheal tube are evolving after more than 3 decades of ...

Pediatric (PARDS) and neonatal (NARDS) acute respiratory distress syndrome have different age-specific characteristics and definitions. Trials on surfactant for ARDS in children and neonates have been performed well before the PARDS and NARDS ...

Surfactant has revolutionized the treatment of respiratory distress syndrome and some other respiratory conditions that affect the fragile neonatal lung. Despite its widespread use, the optimal method of surfactant administration in preterm infants has yet to be clearly determined.